Tech Company Financing Transactions

Zucara Therapeutics Funding Round

Zucara Therapeutics, operating out of Toronto ON, secured $20 million from Perceptive Xontogeny Venture Fund, Sanofi Ventures and private investors.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

661 University Ave. 1300
Toronto ON, M5G 0B7
Canada

Phone

Undisclosed

Website

www.zucara.ca

Email Address

Not Recorded

Overview

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Michael Riddell

        

Chief Executive Officer

Michael Midmer

        

Chief Scientific Officer

Richard Liggins

        

VP - Regulatory Affairs

Susan Peers

        

Browse more venture capital transactions:

Prev: 11/12/2024: Vega Investment Technologies venture capital transaction
Next: 11/12/2024: Ooodles venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to report on every notable VC transaction. VC transactions reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary